AlphaStar Capital Management LLC Acquires 617 Shares of Humana Inc. (NYSE:HUM)

AlphaStar Capital Management LLC boosted its stake in Humana Inc. (NYSE:HUM) by 96.4% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,257 shares of the insurance provider’s stock after purchasing an additional 617 shares during the period. AlphaStar Capital Management LLC’s holdings in Humana were worth $470,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Mendota Financial Group LLC boosted its stake in shares of Humana by 9.2% in the 2nd quarter. Mendota Financial Group LLC now owns 319 shares of the insurance provider’s stock valued at $119,000 after purchasing an additional 27 shares during the last quarter. Aurora Investment Counsel boosted its position in Humana by 1.3% during the fourth quarter. Aurora Investment Counsel now owns 2,273 shares of the insurance provider’s stock valued at $1,155,000 after acquiring an additional 29 shares during the last quarter. Brighton Jones LLC grew its holdings in Humana by 6.8% during the 4th quarter. Brighton Jones LLC now owns 470 shares of the insurance provider’s stock worth $215,000 after acquiring an additional 30 shares during the period. Capital Advisors Ltd. LLC raised its position in shares of Humana by 17.0% in the 2nd quarter. Capital Advisors Ltd. LLC now owns 213 shares of the insurance provider’s stock worth $80,000 after acquiring an additional 31 shares in the last quarter. Finally, Merit Financial Group LLC lifted its stake in shares of Humana by 2.1% in the 4th quarter. Merit Financial Group LLC now owns 1,770 shares of the insurance provider’s stock valued at $810,000 after purchasing an additional 37 shares during the period. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Humana Stock Performance

HUM traded down $2.80 during trading on Tuesday, hitting $350.20. 201,957 shares of the company traded hands, compared to its average volume of 1,647,969. The stock’s fifty day moving average is $367.67 and its 200 day moving average is $346.48. The company has a quick ratio of 1.67, a current ratio of 1.66 and a debt-to-equity ratio of 0.70. Humana Inc. has a one year low of $298.61 and a one year high of $530.54. The firm has a market cap of $42.20 billion, a P/E ratio of 21.98, a price-to-earnings-growth ratio of 2.09 and a beta of 0.51.

Humana (NYSE:HUM) last issued its earnings results on Wednesday, July 31st. The insurance provider reported $6.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.89 by $1.07. Humana had a return on equity of 16.12% and a net margin of 1.53%. The firm had revenue of $29.54 billion for the quarter, compared to analyst estimates of $28.52 billion. During the same period in the previous year, the company posted $8.94 earnings per share. The business’s revenue was up 10.4% on a year-over-year basis. As a group, equities analysts predict that Humana Inc. will post 16.14 EPS for the current fiscal year.

Humana Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Monday, September 30th will be given a $0.885 dividend. This represents a $3.54 annualized dividend and a dividend yield of 1.01%. The ex-dividend date of this dividend is Monday, September 30th. Humana’s dividend payout ratio (DPR) is presently 22.04%.

Analyst Ratings Changes

Several research firms recently commented on HUM. Bank of America raised their target price on Humana from $342.00 to $376.00 and gave the stock a “neutral” rating in a research note on Monday, May 20th. Robert W. Baird started coverage on shares of Humana in a research note on Thursday, May 30th. They issued a “neutral” rating and a $374.00 price objective for the company. Oppenheimer increased their target price on shares of Humana from $370.00 to $400.00 and gave the stock an “outperform” rating in a research note on Thursday, August 1st. Truist Financial lifted their price target on shares of Humana from $355.00 to $400.00 and gave the company a “hold” rating in a research note on Monday, July 15th. Finally, Cantor Fitzgerald reiterated a “neutral” rating and set a $395.00 price objective on shares of Humana in a report on Monday, August 19th. Thirteen research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Humana has an average rating of “Hold” and a consensus target price of $396.35.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.